DIABETOLOGIA Journal
Overview
publication venue for
- Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes 2023
- A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes 2023
- Effect of ertugliflozin on body weight and HbA1cby baseline BMI: observations from VERTIS CV 2023
- Factors associated with changes in beta hydroxybutyrate with sotagliflozin in adults with type 1 diabetes 2023
- Safety and tolerability of multiple ascending doses of once-weekly GL0034 (utreglutide) in healthy individuals 2023
- Effects of a novel long acting GIP/GLP-1/Glucagon tri-receptor agonist, HISHS-3001, on HbA(1c), body weight and lipid metabolism 2022
- Effects of ertugliflozin on uric acid and gout-related outcomes: post hoc analyses from VERTIS CV 2022
- Efficacy of ertugliflozin (ERTU) on hospitalisation for heart failure (HHF) across the spectrum of pre-trial ejection fraction (EF): post hoc analyses of VERTIS CV 2022
- Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter] 2022
- A novel, long-acting dual agonist for GIPR/GLP-1R, HISHS-2001, demonstrates effects on HbA(1c) and weight loss in the db/db mouse model of type 2 diabetes 2021
- Body weight loss with oral semaglutide is predominantly mediated by effects other than gastrointestinal adverse events 2021
- Cardiorenal outcomes with ertugliflozin by baseline cardiorenal medications: an analysis from VERTIS CV 2021
- Cardiorenal outcomes with ertugliflozin by baseline glucose-lowering agent: an analysis from VERTIS CV 2021
- Efficacy and safety of GLP-1RAs with or without baseline SGLT-2i: post hoc analysis of the SUSTAIN 10 trial 2021
- Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV 2021
- Glycaemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from VERTIS CV 2021
- Incorporating treatment pauses, dosing flexibility and education to support GLP-1RA therapy persistence: data from PIONEER 6 2021
- Long-term effects of ertugliflozin (ERTU) on liver enzymes and indices in patients with type 2 diabetes: analyses from VERTIS CV 2021
- Reduced glycaemic variability with once-weekly semaglutide vs active comparators in post hoc analysis of the SUSTAIN programme 2021
- Twenty-four hour assessments of substrate oxidation reveal differences in metabolic flexibility in type 2 diabetes that are improved with aerobic training 2021
- Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. 64:1256-1267. 2021
- Muscle insulin resistance in type 1 diabetes with coronary artery disease. 63:2665-2674. 2020
- Development of an evidence-based tool to facilitate individualised treatment decisions for patients with type 2 diabetes in the clinic 2020
- Renoprotection with semaglutide and liraglutide: Direct or indirect effects? 2020
- Effects of efpeglenatide on weight, BMI, and waist circumference in those with obesity without diabetes stratified by baseline characteristics: subanalysis of BALANCE 205 2019
- Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7 2019
- Efficacy of efpeglenatide in patients with obesity and prediabetes: a subanalysis of the BALANCE 205 study 2019
- Efficacy of oral semaglutide according to diabetes duration: an exploratory subgroup analysis of the PIONEER trial programme 2019
- Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER 2019
- Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials 2019
- Liraglutide and semaglutide improve cardiovascular and renal outcomes across baseline BP categories: analysis of LEADER and SUSTAIN 6 2019
- Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials 2019
- Pooled analysis of the safety and efficacy of ertugliflozin in the elderly 2019
- Chronic kidney disease and risk of mortality, cardiovascular events and severe hypoglycaemia in type 2 diabetes: DEVOTE results 2018
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV) 2018
- Effect of liraglutide on cardiovascular outcomes in elderly patients in the LEADER trial 2018
- Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial 2018
- Liraglutide effects in insulin-treated patients in LEADER 2018
- Rates of major adverse cardiovascular events and mortality with basal insulin by liraglutide use: a DEVOTE sub-analysis 2018
- The effect of efpeglenatide on lipid profiles and overall metabolism in patients with type 2 diabetes and obese patients without diabetes 2018
- Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass. 61:1142-1154. 2018
- DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. 61:58-65. 2018
- Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). 61:48-57. 2018
- Exercise training response heterogeneity: physiological and molecular insights 2017
- A long-term, open-label extension study to investigate the long-term safety of alogliptin in subjects with type 2 diabetes 2017
- Exploring the impact of liraglutide on diabetic foot ulcers on subjects with type 2 diabetes and increased risk of cardiovascular events: results from the LEADER trial 2017
- Safety and efficacy of ertugliflozin plus sitagliptin vs either treatment alone after 52 wks in patients with type 2 diabetes poorly controlled on metformin: VERTIS FACTORIAL extension 2017
- Comparison of two treatment approaches in older patients with type 2 diabetes (IMPERIUM) 2016
- Safety and efficacy of ertugliflozin plus sitagliptin versus either treatment alone in subjects with type 2 diabetes inadequately controlled with metformin: the VERTIS FACTORIAL trial 2016
- ANT1-mediated fatty acid-induced uncoupling as a target for improving myocellular insulin sensitivity. 59:1030-1039. 2016
- Significant effects of HM11260C on body weight over 20 weeks in obese subjects without diabetes: a randomised, double-blind, placebo controlled study 2015
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. 57:2475-2484. 2014
- The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare? 2014
- Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes. 57:623-632. 2014
- HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus 2013
- Lorcaserin HCl phase 3 trials in obese and overweight patients: week 52 outcomes for those achieving at least 5% weight loss at week 12: a per prescribing information analysis 2013
- Alogliptin plus metformin combination therapy vs alogliptin or metformin monotherapy for type 2 diabetes mellitus 2012
- Changes in insulin sensitivity as measured by glucose disposal rate and acute insulin secretion with the sodium glucose co-transporter 2 inhibitor dapagliflozin 2011
- Does rimonabant independently affect NEFA and glucose metabolism? 2011
- Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide. 54:1147-1156. 2011
- Strong association between mitochondrial DNA copy number and lipogenesis in human white adipose tissue. 50:2526-2533. 2007
- Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. 48:301-308. 2005
- Identification of differentially expressed genes in skeletal muscle of non-diabetic insulin-resistant and insulin-sensitive Pima Indians by differential display PCR. 46:1567-1575. 2003
- Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. 45:1584-1593. 2002
- The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus 2001
- Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. 43:1498-1506. 2000
- Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. 43:36-46. 2000
- Visceral adipose tissue is not increased in Pima Indians compared with equally obese Caucasians and is not related to insulin action or secretion. 42:28-34. 1999
- Plasma leptin concentrations: no difference between diabetic Pima Indians with and without nephropathy 1998
- beta(3)-Adrenergic receptor gene variant and lipid metabolism in Pima Indians 1997
Research
category
- ENDOCRINOLOGY & METABOLISM Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 0012-186X
Electronic International Standard Serial Number (EISSN)
- 1432-0428
Other
journal abbreviation
- DIABETOLOGIA